ABSTRACT
INTRODUCTION
Interventional treatments for atherosclerotic intracranial arterial stenosis (AIAS) have been introduced more than a decade ago, and have evolved from balloon angioplasty to balloon angioplasty with stenting to self-expanding stenting. At present, there are two main types of stents for intracranial stenosis: the balloon-expandable stent and the self-expanding stent.
Compared with balloon-expandable stents, self-expanding stents have better flexibility for an easier approach to the target vessels, a hydrophilic coating to reduce intimal injuries, and a sub-satisfactory balloon dilation to decrease the risk of vascular rupture (9) . Park et al (19) found in their controlled study on the comparison of intracranial self-expanding and balloon-expandable stents that both stent types could im-prove prognosis, but adverse events with the self-expanding stent were significantly lower than with the balloon expandable stent.
The Wingspan system was the earliest intracranial self-expanding stent used clinically. Developed by Boston Scientific Corporation, the Wingspan stent adopts a Gateway balloon with a slightly smaller diameter than the target vessel to perform sub-satisfactory dilation and then implants a self-expanding stent with a slightly larger diameter than the target vessel. Early clinical studies revealed that Wingspan stenting was safe during the perioperative period while maintaining a high technical success rate (3) . However, a recent large-scale multi-center study in high-risk patients with intracranial artery stenosis (SAMMPRIS) reached a different conclusion (5) . That study was terminated because the incidence of stroke and death in the Wingspan stent group within 30 days was significantly higher than those of the control group, and the adverse events in the Wingspan stent group were twice as many than expected (2) . Some researchers believed that the high radial strength of the Wingspan stent might be one of the reasons for the high postoperative restenosis rate (24) .
The Enterprise stent was designed as an adjuvant stent for embolization of intracranial aneurysms and has been widely used for that procedure (10-12, 14, 17, 20) . As a self-expanding stent similar to the Wingspan stent, the Enterprise stent is a closed-loop stent with a different design compared with the Wingspan stent ( Figure 1A -C). Krischek et al (15) conducted an in vitro study comparing the functional and physical properties of self-expanding intracranial stents and the results indicated that, compared with the Wingspan stent, the Enterprise stent has less radial strength and better flexibility and transportability, which enable more precise positioning and release. After SAMMPRIS, a study has investigated the use of the Enterprise stent in AIAS, and showed that the Enterprise stent was safe and effective to treat AIAS (24) .
The aim of the present study was to assess the safety and efficacy of the Enterprise stent in treating AIAS in a Chinese patient population. This should provide additional information for the use of the Enterprise stent for AIAS in selected patients.
MATERIAL and METHODS

Patients
This was a retrospective study conducted with 60 patients with 62 lesions admitted to the Neurosurgery Department of the Second Hospital of Shandong University between June 2012 and January 2014 and treated using Enterprise stents (Codman, US). These patients were consecutively admitted and newly diagnosed. Diagnosis was confirmed by digital subtraction angiography (DSA).
In our hospital, patients found with symptomatic AIAS are initially treated with aspirin 300 mg qd (or 100 mg qd for patients with tendency to bleed with medication), Plavix 75 mg qd, and atorvastatin 20 mg qn. If the symptoms remain, they become eligible for stenting. Patients experiencing a second transient ischemic attack (TIA) or minor stroke during medication are immediately eligible for stenting. Additional eligibility criteria for stenting were: 1) symptomatic intracranial arterial stenoses with symptoms consistent with the vascular lesions in the blood-supplied regions; 2) cerebral artery with a stenosis rate ≥50% with an inadequate perfusion confirmed by computed tomography (CT) and magnetic resonance (MR) perfusion-weighted imaging; 3) stenotic sites located at the internal carotid artery, M1 segment of the middle cerebral artery, intracranial vertebral artery or basilar artery, and the feasibility of implantation of balloons and stents was predicted operatively; and 4) patients with a modified Rankin score (mRS) of ≤3 points.
Exclusion criteria were: 1) non-atherosclerotic (arteritis, or induced by other factors such as the moyamoya disease) intracranial arterial stenosis; 2) arterial dissection; or 3) acute cerebral infarction within two weeks.
This study was approved by the Ethical Committee of the Second Hospital of Shandong University. All patients involved in the study signed an informed consent preoperatively.
Study Design
Preoperative MR and CT imaging (Siemens, Erlangen, Germany) and routine neurological examinations were performed. Using the Innova 3100 IQ digital flat-panel angiography instrument (GE Healthcare, Buckinghamshire, UK), cerebral angiography was performed prior to the treatments. The size of the Gateway balloon was selected as 80% of the diameter of the vessel that was proximal to the stenosis. The balloon was dilated slowly, with a final pressure of 607.950-1013.250 kPa (6-10 atm) for 30 seconds. The stent diameter was 1.5 mm wider than that of the target vessel, and the exceeding length of the stent was at least 3 mm longer than that of the target lesion. The stent was placed using standard techniques. The surgery was terminated if angiography performed immediately after stenting showed that all the stents were patent without thrombosis or perforating artery occlusion. All the surgeries were performed by the director of the Neurosurgery department (more than 20 years expertise in neurological interventional treatments).
The postoperative systolic blood pressure was maintained at <120 mmHg. For postoperative medications, aspirin 300 mg/d (or 100 mg/d for patients with tendency to bleed) was prescribed for the first month and the dose was adjusted to 100 mg/d from the second month and maintained for life. Clopidogrel 75 mg/d was prescribed for 3 months. If ischemic events appeared, another 6 months of clopidogrel was given.
Clinical Data Collection and Examination
The observations indices included patient age, sex, symptoms, stenotic site, diameter of the normal vessel proximal to the stenosis, stenotic degree, stenotic length, Mori classification, models of the balloons and stents, post-stent residual stenosis rate, perioperative complications, modified Rankin scoring system (mRS) scores at discharge, and mortality rate within 30 days postoperatively.
Clinical follow-ups and DSA were performed at 1, 3, 6 and 12 months postoperatively. Observation indices of the followups included in-stent restenosis (ISR) rate, recurrent ischemic events and deaths of various causes. ISR was defined as a lesion with a stenosis rate greater than 50%. Immediate postoperative residual stenosis was defined as a rate ≥ 30%.
Statistical Analysis
Data are presented as values with percentages, means ± SD and range, as appropriate. Statistical analysis was performed with SPSS 19.0 (IBM, Armonk, NY, USA). Univariate and multivariate analyses were performed to evaluate whether site of the lesion and rate of residual stenosis were independent risk factors for ISR. Since the sample size was small, only residual stenosis rate, stenotic length (≥8 mm and <8 mm), and age were included in the multivariate analysis. P<0.05 was considered statistically significant.
RESULTS
Baseline Patient Characteristics
Of the 60 AIAS patients with 62 lesions who received treatment using the Enterprise stent, 42 (70%) were men and 18 (30%) were women. Their mean age was 56.8±8.0 years old (age range: 28-68 years old). All patients had symptomatic stenoses, 38 (63.3%) of which were transient ischemic attack (TIA) and 22 (36.7%) were ischemic stroke.
Treatment Regimen
The details of the 62 lesions included in this study are shown in Table I . Stenting was performed within 1 week of symptom occurrence for patients with TIA and between 2 weeks and 30 days for patients with ischemic stroke. Of the 62 lesions, 14 (22.6%) were located in the anterior circulation and 48 (77.4 %) were located in the posterior circulation; 10 were in the internal carotid artery, 4 in the M1 segment of the middle cerebral artery, 20 in the intracranial vertebral artery, and 28 in the basilar artery. Seven were Mori A lesions, 48 were Mori B lesions and 7 were Mori C lesions. Sixty were type I + type II lesions, and only 2 were type III lesions (according to the classifications of location, morphology and access). Twentyfour (38.7%) had a stenosis rate of 50-70%, 38 (61.3%) had a stenosis rate of 70-99%, and the mean stenosis rate was 76.3±12.7%. The mean stenotic vessel length was 7.7±2.0 mm (length range: 4-12.3 mm). The mean diameter of the proximal segment of the stenotic vessel was 2.8±0.3 mm (diameter range: 1.8-3.5 mm). The mean post-stent residual stenosis rate was 22.8±4.8% (rate range: 15-35%).
Treatment
The technical success rate in this study was 100%. Only Gateway balloons (Boston Scientific Corporation, Marlborough, MA, USA) were used, of which 6 were 2.0×9 mm, 10 were 2.0×15 mm, 17 were 2.25×9 mm, 8 were 2.25×15 mm, 10 were 2.5×9 mm, 5 were 2.5×15 mm, 1 was 2.75×9 mm, and 5 were 2.75×15 mm. The inflation pressure was controlled between 6 and 10 atm. A total of 62 Enterprise stents were implanted, and 36 of them were 4.5×14 mm and 26 were 4.5×22 mm.
Complications
Of the 60 patients, only 5 (8.3%) had perioperative complications. There was one case of in-stent thrombosis: the thrombus disappeared after thrombolytic therapy with 400,000 U of urokinase delivered by microcatheter. There was one case of in-stent dissection: the patient was asymptomatic and the dissection was found to have self-healed at the 6-month follow-up. There was one case of intraoperative vertebral artery spasm: the symptoms were relieved after topical nimotop and papaverine application. Two patients had ischemic strokes within 30 days postoperatively. The mortality rate within the 30 days was 0%. Patients' mRS scores were as follows: 0 in 42 cases, 1 in 13 cases, 2 in 3 cases, and 3 in 1 case, and 4 in 1 case.
The follow-up duration was between 1 and 12 months, with a mean of 6.2 months.
Six months postoperatively, 45 lesions (72.6%) were examined by DSA, and 6 (13.3%) lesions were confirmed to be postoperative restenoses (stenosis rate ≥50%), 2 of which were anterior (20% of the 10 anterior lesions that were followed up), and 4 of which were posterior (11.4% of the 35 posterior lesions that were followed up). Representative cases are shown in Figures 2A-D, 3A-D, 4A-D. Figures 2A-D and 3A -D show cases that had a high grade stenosis that was successfully treated and showed no restenosis. Figure 4A -D shows a case that was successfully treated for a high grade stenosis but experienced ISR. Of the 6 restenosis lesions, 4 (66.7%) were immediate residual stenoses after stenting which had a stenosis rate of no smaller than 30% (Table II) . During followup, 5 (8.3%) ischemic events (2 strokes and 3 ITAs) occurred, which were consistent with the vascular lesions in the blood supplying regions. Of the 39 cases without restenoses, DSA indicated that 33 (84.6%) had a residual stenosis rate smaller than the corresponding immediate postoperative stenosis rate.
Risk Factors for ISR
The results of univariate and multivariate analysis are shown in Table III . Multivariate analysis identified post-stenting residual stenosis rate as a risk factor for ISR (P=0.005, odds ratio 37.485 95% CI 2.955-475.539).
DISCUSSION
The aim of this study was to evaluate the efficacy and safety of Enterprise stents in the treatment of AIAS. The technical success rate was 100% and the incidence of perioperative complications was low. The postoperative restenosis rate was 13.3%. A recent study have also used Enterprise stents for AIAS (24) , but the present study is the first in a Chinese population, and the results should provide additional important information on the choice of stent for percutaneous transluminal angioplasty and stenting (PTAS).
There are two approaches to treating AIAS, drug therapy and surgical therapy. The Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) trial indicated that the incidence of stroke in the area supplied by the affected vessels in patients with a stenosis rate of 50-99% who received warfarinaspirin therapy was 11% within 1 year and 14% within 2 years postoperatively (4). However, a US multi-center, prospective, randomized control study compared the efficacy between extracranial-intracranial arterial bypass and drug therapy on cerebral vascular stenosis and did not prove the efficacy of extracranial-intracranial arterial bypass on ischemic stroke (1). PTAS has been an alternative choice for the treatment of symptomatic AIAS, which has received increasing interest. The incidence of adverse events in PTAS has significantly decreased with technical advances (8) .
A thorough preoperative evaluation is vital for the evaluation of any stenting method since intracranial stenting is rather classification since they believed that access is an important prognostic factor for successful stent-assisted angioplasty. Therefore, they proposed the classification system of location, morphology and access (LMA) and found that the success rate was higher in type I lesion than in type III and type II + risky (6) . In 1998, Mori et al (18) proposed a classification system for intracranial stenosis, which helps predicting the success rate and complications of percutaneous transluminal angiography (PTA). However, Jiang et al (13) thought that it was difficult to precisely evaluate the outcomes of the Mori 
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were followed up angiographically and those who were asymptomatic but with intimal hyperplasia were not followed up. Vajda et al (24) treated 189 patients with AIAS (with 209 lesions) using the Enterprise stent, and reached a DSA followup rate of 83%; they found that the restenosis rate was 24.7%, lower rate than that of Wingspan (31.2%). Turk et al (23) have found that more ISR occurred with anterior circulation lesions, especially those involving the supraclinoid segment, in younger patients with Wingspan stents. An ISR is defined as a post-stenting stenosis rate >50%. Theoretically, the higher the residual stenosis rate, the higher risk is for ISR. Yue et al (25) showed that ISR rate in nonresidual (≤30%) and residual (>30%) stenosis groups was 17.0% and 45.5%, respectively. Therefore, residual stenosis is an independent risk factor for ISR. In the present study, 4 (66.7%) of the 6 patients with ISR had lesions with an immediate postoperative residual stenosis ≥30%. The multivariate analysis presented here also revealed that residual stenosis was a risk factor for ISR.
Intimal hyperplasia is the main reason for ISR, since the overdilated vessels may tear the plaques and intima, resulting in hyperplasia of the endothelial and smooth muscle cells. Shin et al (22) found that rapid balloon inflation and longer lengths of stenosis were independent risk factors for ISR using the Wingspan stent. In the present study, we tried our best to use 80% of the diameters of the normal vessels proximal to the lesions as selection criteria for the balloon sizes. Additionally, as well as controlling the final pressure at a level of <10 atm, we also abandoned the post-balloon treatments to avoid intimal injuries and ISR caused by rapid balloon inflation or over-dilation.
In the present study, 6 (13.3%) of the 45 lesions followed up by DAS had ISR 6 months postoperatively, including 5 symptomatic ISR and 1 asymptomatic intimal hyperplasia, which was lower than the rates reported by the US Multicenter Wingspan Registry (26) and Vajda et al (24) . The ISR rate was 20% for anterior circulation lesions and 11.4% for posterior circulation lesions. Therefore, the high overall lesion proportion of posterior circulation lesions (which was 77.4%) might be a reason for the low overall ISR rate. The Enterprise stent is a self-expanding stent with less radial strength and no plaque cutting, with little stimulation of the intima after stenting, effectively reducing the ISR rate. Moreover, in the 39 lesions without ISR, 33 (84.6%) had a residual stenosis rate smaller than the corresponding immediate postoperative stenosis rate, indicating that consistent post-stenting and low radial strength of the Enterprise stent contributed to the gradual restoration of the stenotic vessels.
LIMITATIONS
The retrospective nature of this study resulted in some unavoidable limitations. The Enterprise stent needs to be fully and carefully evaluated using a randomized controlled clinical trial. Until then, retrospective studies like the present study must be relied upon to provide information to surgeons on methods for treating AIAS. Although this study demonstrated a trend towards a higher risk of IRS in patients with anterior III lesions. Indeed, of the 62 lesions in the present study, 60 were type I + II lesions and only 2 were type III lesions, which probably helped in achieving the high surgical success rate observed here.
Although techniques are constantly improving, adverse events still occur during and after stenting for AIAS. In a study by Park et al (19) , the incidence of adverse events were significantly lower in patients receiving self-expendable stents compared with those receiving balloon-expendable stents. Indeed, self-expandable stents reduce the risk of injury to the artery (7). In the INTRASTENT study, the risk of hemorrhage was relatively high when treating middle cerebral artery stenosis, probably due to the fact that it is relatively difficult to deliver the wire in ultraselection, increasing the risk of damaging the arteries (16) . Both the Enterprise and the Wingspan stent are self-expandable stents. Krischek et al (15) have shown that the Enterprise stent has a better flexibility and is easier to deliver than the Wingspan stent, reducing the risk of damaging the arteries. This could explain, at least in part, the high technical success rate of 100% observed in the present study. In addition, only 5 (8.3%) patients had perioperative complications and the mortality rate within 30 days was 0%, which was lower than the results of the SAMMPRIS trial (5). The thorough preoperative evaluation and steady control of intra-and postoperative blood pressure could explain the absence of cases with reperfusion hemorrhage in the present study. Although preoperative dual antiplatelet therapy was used in all patients using aspirin and clopidogrel, temporary in-stent thrombosis still occurred in one patient intraoperatively and two patients suffered from stroke within 30 days. The patient with in-stent thrombosis was free from bleeding tendencies before the operation, and received the complete anti-platelet regimen of clopidogrel 75 mg/d and aspirin 300 mg/d. The thrombus disappeared using immediate 400,000 U of urokinase locally delivered using a catheter. The increased number of patients with aspirin and clopidogrel resistance may be one of the reasons for the occurrence of perioperative thrombotic complications (21) . Therefore, preoperative monitoring of the patient's response to antiplatelet drugs should be considered as a routine investigation for patients with AIAS who are to receive stentassisted angioplasty. However, there is a lack of studies about the individual anti-platelet regimens before stenting. Studies should be performed to clarify this issue.
At present, a high restenosis rate has been one of the major adverse events in stent-assisted angioplasty of AIAS, while the benefit a patient achieves with stent-assisted angioplasty is decided by the consistency of the recanalization. Therefore, reduction of ISR has been the focus of attention. A recent systematic review (8) strongly suggests that the post-stenting restenosis rate was 13.8% in patients with balloon expandable stents and 17.4% in those with self-expanding stents, while the post-stenting restenosis rate of the Wingspan stent was between 7.5% and 31.2% (3, 23) . Vajda et al (24) believed that the incidence of in-stent restenosis might be underestimated, because in most of the studies only symptomatic patients circulation lesions, we could not verify it through statistical analyses due to the small sample size. The follow-up duration in this study was rather short. Therefore, a study with a longterm systematic DSA and clinical follow-up is required to more accurately reveal the pathological changes and clinical efficacies of the Enterprise stent.
CONCLUSION
With a high technical success rate and low perioperative complication rate, the use of the Enterprise stent in treating AIAS was shown to be safe and efficient in this specific population of AIAS patients. Our results strongly suggested that the ISR rate in Enterprise stenting was lower than most of the currently reported ISR rates in self-expanding stenting.
